A renal metanephric adenoma showing both a 2p16-24 deletion and BRAF V600E mutation: a synergistic role for a tumor suppressor gene on chromosome 2p and BRAF activation?

被引:9
作者
Dadone, Berengere [1 ]
Ambrosetti, Damien [1 ,2 ]
Carpentier, Xavier [3 ]
Duranton-Tanneur, Valerie [4 ]
Burel-Vandenbos, Fanny [2 ]
Amiel, Jean [3 ]
Pedeutour, Florence [1 ,4 ]
机构
[1] Univ Nice Sophia Antipolis, IRCAN, CNRS UMR 7284, INSERM U1081, F-06189 Nice, France
[2] Nice Univ Hosp, Cent Lab Pathol, Nice, France
[3] Nice Univ Hosp, Dept Urol, Nice, France
[4] Nice Univ Hosp, Lab Solid Tumors Genet, Nice, France
关键词
Metanephric adenoma; BRAF V600E mutation; chromosomal imbalance; tumor suppressor gene; short arm of chromosome 2; WILMS-TUMOR;
D O I
10.1016/j.cancergen.2013.09.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metanephric adenomas (MAs) are rare benign tumors that may be difficult to recognize. Specific genetic anomalies might aid in diagnosis, but genomic data are limited and conflicting. Consistent mutations of the BRAF gene have been recently reported in MAs and could become useful as a discriminative marker among renal tumors. We report here a case of MA, showing both a BRAF V600E mutation and a segmental loss within bands 2p16 and 2p24 as the sole quantitative genomic anomaly. We compared the borders and size of the deleted region in our case to those of five cases of MAs previously reported. We identified a common minimal region containing 87 genes, among which several tumor suppressor genes could be candidate actors in the pathogenesis of MA. We ruled out MSH2 and MSH6 as target gene candidates, both located in the deleted region, on the basis of preserved expression and microsatellite sequence stability. Our study confirms the recurrence of a BRAF mutation and of 2p alterations in MAs. This first case showing simultaneous presence of a BRAF mutation and a 2p deletion raises the question of a synergistic role for these two anomalies in the pathogenesis of MAs.
引用
收藏
页码:347 / 352
页数:6
相关论文
共 19 条
[1]   Metanephric neoplasms: The hyperdifferentiated, benign end of the Wilms tumor spectrum? [J].
Argani, P .
CLINICS IN LABORATORY MEDICINE, 2005, 25 (02) :379-+
[2]   Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors [J].
Buhard, O ;
Cattaneo, F ;
Wong, YF ;
Yim, SF ;
Friedman, E ;
Flejou, JF ;
Duval, A ;
Hamelin, R .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (02) :241-251
[3]   Metanephric adenoma of the kidney: a clinicopathological and molecular study of two cases [J].
Burger, Maximilian ;
Junker, Kerstin ;
Denzinger, Stefan ;
Schubert, Thomas ;
Stoehr, Robert ;
Wieland, Wolf-Ferdinand ;
Hartmann, Arndt .
JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (07) :832-834
[4]   Type 2 diabetes risk variants and colorectal cancer risk: the Multiethnic Cohort and PAGE studies [J].
Cheng, Iona ;
Caberto, Christian P. ;
Lum-Jones, Annette ;
Seifried, Ann ;
Wilkens, Lynne R. ;
Schumacher, Fredrick R. ;
Monroe, Kristine R. ;
Lim, Unhee ;
Tiirikainen, Maarit ;
Kolonel, Laurence N. ;
Henderson, Brian E. ;
Stram, Daniel O. ;
Haiman, Christopher A. ;
Le Marchand, Loic .
GUT, 2011, 60 (12) :1703-1711
[5]   BRAF Mutations in Metanephric Adenoma of the Kidney [J].
Choueiri, Toni K. ;
Cheville, John ;
Palescandolo, Emanuele ;
Fay, Andre P. ;
Kantoff, Philip W. ;
Atkins, Michael B. ;
McKenney, Jesse K. ;
Brown, Victoria ;
Lampron, Megan E. ;
Zhou, Ming ;
Hirsch, Michelle S. ;
Signoretti, Sabina .
EUROPEAN UROLOGY, 2012, 62 (05) :917-922
[6]   METANEPHRIC ADENOMA - CLINICOPATHOLOGICAL STUDY OF 50 PATIENTS [J].
DAVIS, CJ ;
BARTON, JH ;
SESTERHENN, IA ;
MOSTOFI, FK .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1995, 19 (10) :1101-1114
[7]  
den Dunnen JT, 2000, HUM MUTAT, V15, P7
[8]   Untitled [J].
Eble, JN .
MODERN PATHOLOGY, 2004, 17 (01) :1-1
[9]  
Erson AE, ATLAS GENET CYTOGENE
[10]   Lack of KRAS and BRAF Mutation in Renal Cell Carcinoma [J].
Gattenloehner, S. ;
Etschmann, B. ;
Riedmiller, H. ;
Mueller-Hermelink, H.-K. .
EUROPEAN UROLOGY, 2009, 55 (06) :1490-1491